Melodiol Global Health reported unaudited revenue of $4.8 million for the second quarter, a 9% increase from the prior quarter's revenue of $4.4 million.

The growth was mainly driven by solid results from the company's subsidiary, Mernova.

During the quarter, Mernova confirmed unaudited purchase orders worth $2 million, a 25% increase from the previous quarter and a 33% increase from a year earlier. Mernova has already secured $452,000 in confirmed purchase orders for the third quarter.

During the second quarter, Melodiol's HHI division also contributed $2.8 million in sales across its Australian and UK markets.